• Citer

Overuse of inhaled corticosteroids in COPD: Five questions for withdrawal in daily practice

par Cataldo, Didier;Derom, Eric;Liistro, Giuseppe;Marchand, Eric;Ninane, Vincent ;Peché, Rudi;Slabbynck, Hans;Vincken, Walter;Janssens, Wim
Référence International journal of chronic obstructive pulmonary disease, 13, page (2089-2099)
Publication Publié, 2018

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Evidence and guidelines are becoming increasingly clear about imbalance between the risks and benefits of inhaled corticosteroids (ICSs) in patients with COPD. While selected patients may benefit from ICS-containing regimens, ICSs are often inappropriately prescribed with – according to Belgian market research data – up to 70% of patients in current practice receiving ICSs, usually as a fixed combination with a long-acting β2-adrenoreceptor agonist. Studies and recommendations support withdrawal of ICSs in a large group of patients with COPD. However, historical habits appear difficult to change even in the light of recent scientific evidence. We have built a collaborative educational platform with chest physicians and primary care physicians to increase awareness and provide guidance and support in this matter.